ATE179862T1 - Rezeptoren für fibroblasten-wachstumsfaktoren - Google Patents

Rezeptoren für fibroblasten-wachstumsfaktoren

Info

Publication number
ATE179862T1
ATE179862T1 AT90911235T AT90911235T ATE179862T1 AT E179862 T1 ATE179862 T1 AT E179862T1 AT 90911235 T AT90911235 T AT 90911235T AT 90911235 T AT90911235 T AT 90911235T AT E179862 T1 ATE179862 T1 AT E179862T1
Authority
AT
Austria
Prior art keywords
growth factor
fibroblast growth
fgf
receptor
methods
Prior art date
Application number
AT90911235T
Other languages
English (en)
Inventor
Lewis T Williams
Daniel E Johnson
Pauline E Lee
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE179862T1 publication Critical patent/ATE179862T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
AT90911235T 1989-07-06 1990-07-06 Rezeptoren für fibroblasten-wachstumsfaktoren ATE179862T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37700389A 1989-07-06 1989-07-06

Publications (1)

Publication Number Publication Date
ATE179862T1 true ATE179862T1 (de) 1999-05-15

Family

ID=23487374

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90911235T ATE179862T1 (de) 1989-07-06 1990-07-06 Rezeptoren für fibroblasten-wachstumsfaktoren

Country Status (15)

Country Link
US (4) US6384191B1 (de)
EP (1) EP0481000B1 (de)
JP (1) JP3039802B2 (de)
KR (1) KR100235266B1 (de)
AT (1) ATE179862T1 (de)
AU (1) AU638734B2 (de)
CA (1) CA2063431C (de)
DE (1) DE69033109T2 (de)
DK (1) DK0481000T3 (de)
ES (1) ES2133271T3 (de)
FI (1) FI920027A0 (de)
HU (1) HU215581B (de)
NO (1) NO310032B1 (de)
SG (1) SG72657A1 (de)
WO (1) WO1991000916A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001466D0 (en) * 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
US6384191B1 (en) 1989-07-06 2002-05-07 Regents Of The University Of California Receptors for fibroblast growth factors
JP2552942B2 (ja) * 1990-06-01 1996-11-13 三井東圧化学株式会社 ヒトｂーＦＧＦ受容体遺伝子
DE69133281T2 (de) * 1990-07-06 2004-05-06 Gencell S.A. Rezeptoren der wachstumsfaktoren aus fibroblasten
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
IL100219A0 (en) * 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
DK0646182T3 (da) * 1992-06-18 1996-09-16 Whittier Inst Diabetes & Endoc Fremgangsmåde til påvisning af neoplastiske sygdomme
EP1975181B1 (de) * 1992-10-28 2011-02-16 Genentech, Inc. Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6214795B1 (en) 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
WO1999055861A2 (en) * 1998-04-28 1999-11-04 Eisai Co., Ltd. Fibroblast growth factor mutein compositions and methods of use therefor
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20020192719A1 (en) * 1998-09-30 2002-12-19 Caliper Technologies Corp. Homogeneous assay methods
AU3224700A (en) 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
RU2294761C2 (ru) * 1999-05-14 2007-03-10 Имклон Систимс Инкопэритид Лечение резистентных опухолей человека антагонистами рецепторов фактора роста эпидермиса
CA2418083A1 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
JP4262979B2 (ja) 2000-11-21 2009-05-13 ザ・テキサス・エイ・アンド・エム・ユニバーシテイ・システム Ｆｇｆアフィニティークロマトグラフィー
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
AU2002329540A1 (en) 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
ATE276755T1 (de) * 2002-02-28 2004-10-15 Switch Biotech Ag Verwendung eines fibroblastenwachstumsfaktor- bindeproteins zur behandlung und diagnose von diabetischen wundheilugnsstörungen
WO2003072126A2 (de) * 2002-02-28 2003-09-04 Switch Biotech Ag Verwendung eines fibroblastenwachstumsfaktor-bindeproteins zur behandlung und diagnose von diabetischen wundheilungsstörungen
US20060281130A1 (en) 2002-12-20 2006-12-14 Elisabeth Bock Metod of modulation of interaction between receptor and ligand
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
CA2550245A1 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
DK1735348T3 (da) * 2004-03-19 2012-07-16 Imclone Llc Humant anti-epidermalt vækstfaktorreceptorantistof
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
DE602006010874D1 (de) 2005-07-22 2010-01-14 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
EP2121743B1 (de) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Gezielte therapeutika auf der basis von manipulierten proteinen für tyrosinkinaserezeptoren, einschliesslich igf-ir
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
MX2010008874A (es) 2008-02-14 2010-09-22 Bristol Myers Squibb Co Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
CN102099373A (zh) 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
RU2509774C2 (ru) * 2008-08-04 2014-03-20 Файв Прайм Терапьютикс, Инк. Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
PT2365828E (pt) * 2008-11-07 2014-12-12 Galaxy Biotech Llc Anticorpos monoclonais para o receptor 2 do factor de crescimento de fibroblastos
BRPI1006448B1 (pt) 2009-03-25 2021-08-17 Genentech, Inc Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, micro­organismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3
TWI560197B (en) 2009-05-05 2016-12-01 Amgen Inc Fgf21 mutants and uses thereof
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010148142A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
CA2780457A1 (en) 2009-11-13 2011-05-19 Five Prime Therapeutics, Inc. Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
US8372952B2 (en) * 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
US8435525B1 (en) 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
SG185487A1 (en) 2010-05-11 2012-12-28 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
SG190788A1 (en) 2010-11-15 2013-07-31 Five Prime Therapeutics Inc Fgfr1 extracellular domain combination therapies
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
CA2855818A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression
TWI679021B (zh) 2013-08-01 2019-12-11 美商戊瑞治療有限公司 無海藻糖基化抗fgfr2iiib抗體
US10373702B2 (en) * 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
AU2015320341B2 (en) 2014-09-26 2021-05-27 Rajendra Sahai Bhatnagar Inhibitors of NF kappa-B activity for treatment of diseases and disorders
CA2988299C (en) 2015-06-05 2023-10-31 Ibio, Inc. Endostatin fragments and variants for use in treating fibrosis
MX2018006181A (es) 2015-11-23 2018-09-24 Five Prime Therapeutics Inc Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
WO2018213304A1 (en) 2017-05-16 2018-11-22 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
IL300623A (en) 2020-08-21 2023-04-01 Genzyme Corp Anti-FGFR3 antibodies and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394443A (en) 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4785079A (en) * 1984-11-09 1988-11-15 The Salk Institute For Biological Studies Isolation of fibroblast growth factor
US4668476A (en) * 1984-03-23 1987-05-26 Applied Biosystems, Inc. Automated polypeptide synthesis apparatus
US4761371A (en) 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5057417A (en) * 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
US4968607A (en) * 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
SE8804164A0 (sv) * 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6384191B1 (en) 1989-07-06 2002-05-07 Regents Of The University Of California Receptors for fibroblast growth factors
US5229501A (en) * 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
US6022741A (en) * 1997-03-13 2000-02-08 University Of North Carolina At Chapel Hill Regulatory genetic DNA that regulates the Class II transactivator (CIITA)

Also Published As

Publication number Publication date
JP3039802B2 (ja) 2000-05-08
HU215581B (hu) 1999-01-28
WO1991000916A2 (en) 1991-01-24
CA2063431A1 (en) 1991-01-07
WO1991000916A3 (en) 1991-10-17
ES2133271T3 (es) 1999-09-16
AU6077990A (en) 1991-02-06
FI920027A0 (fi) 1992-01-03
US6355440B1 (en) 2002-03-12
NO920060D0 (no) 1992-01-03
AU638734B2 (en) 1993-07-08
HUT61052A (en) 1992-11-30
NO310032B1 (no) 2001-05-07
CA2063431C (en) 2002-10-29
DE69033109D1 (de) 1999-06-17
EP0481000A4 (en) 1992-10-21
JPH04506604A (ja) 1992-11-19
KR100235266B1 (en) 1999-12-15
US5707632A (en) 1998-01-13
US6384191B1 (en) 2002-05-07
NO920060L (no) 1992-03-02
HU906195D0 (en) 1992-06-29
DE69033109T2 (de) 1999-11-18
EP0481000A1 (de) 1992-04-22
DK0481000T3 (da) 1999-11-15
US6350593B1 (en) 2002-02-26
SG72657A1 (en) 2000-05-23
EP0481000B1 (de) 1999-05-12

Similar Documents

Publication Publication Date Title
DE69033109D1 (de) Rezeptoren für fibroblasten-wachstumsfaktoren
D'Andrea et al. Expression cloning of the murine erythropoietin receptor
Gearing et al. Expression cloning of a receptor for human granulocyte‐macrophage colony‐stimulating factor.
Wang et al. Expression cloning and characterization of the TGF-β type III receptor
EP0555989B1 (de) TGF-Beta induziertes Gen und Protein
Moreau et al. Leukaemia inhibitory factor is identical to the myeloid growth factor human interleukin for DA cells
Kondo et al. Expression of functional human interleukin-2 receptor in mouse T cells by cDNA transfection
CA2076979C (en) Substantially pure transforming growth factor-.beta.-1-binding protein and nucleotide sequences expressing the binding protein
Barry et al. Two contiguous residues in human interleukin-3, Asp21 and Glu22, selectively interact with the alpha-and beta-chains of its receptor and participate in function.
DE69638022D1 (de) Aus wirbeltieren und darauf basierende verfahren
DK0861261T3 (da) Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå
WO1999055865A1 (en) Polynucleotides isolated from skin cells and methods for their use
BartňÏk et al. Avian stem cell factor (SCF): production and characterization of the recombinant His-tagged SCF of chicken and its neutralizing antibody
AU637133B2 (en) Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO2000069884A2 (en) Compositions isolated from skin cells and methods for their use
ES2134771T5 (es) Adn que codifica el receptor del factor estimulador de una colonia de granulocitos.
Fabisiak et al. Platelet-derived growth factor
Too et al. Prolactin induces expression of FGF-2 and a novel FGF-responsive NonO/p54nrb-related mRNA in rat lymphoma cells
Axelrod et al. The interferon-gamma receptor extracellular domain. Non-identical requirements for ligand binding and signaling.
EP0490410B1 (de) TXA2-Rezeptor und dafür kodierendes Gen
Minamoto et al. Ligand-dependent selection of the receptor gene: segregation of IL-2 binding activity and anti-Tac reactivity by a single amino acid alteration in the Tac antigen (p55)
Zhang et al. Amino acids 67 and 68 of transforming growth factor-β regulate binding to a glycosyl phosphatidyl inositol-linked membrane protein on vascular endothelial cells
AU699824B2 (en) DNA sequence coding for a BMP receptor
Betsholtz et al. Platelet-derived growth factor—Structural and functional aspects of the A-chain gene
Kimberley et al. The HSPG binding domain of APRIL serves as a platform for ligand multimersation and cross-linking.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time